Extracellular Superoxide Dismutase Attenuates Renal Oxidative Stress Through the Activation of Adenosine Monophosphate-Activated Protein Kinase in Diabetic Nephropathy
Overview
Authors
Affiliations
Aims: Oxidative stress plays a crucial role in the pathogenesis of diabetic nephropathy (DN). We evaluated whether extracellular superoxide dismutase (EC-SOD) has a renoprotective effect through activation of adenosine monophosphate-activated protein kinase (AMPK) in diabetic kidneys.
Results: Human recombinant EC-SOD (hEC-SOD) was administered to 8-week-old male C57BLKS/J db/db mice through intraperitoneal injection once a week for 8 weeks. Renal SOD3 expression was suppressed in db/db mice, which was significantly enhanced by hEC-SOD treatment. hEC-SOD improved albuminuria, mesangial expansion, and interstitial fibrosis in db/db mice. At the molecular level, hEC-SOD increased phosphorylation of AMPK, activation of peroxisome proliferative-activated receptor γ coactivator 1α (PGC-1α), and dephosphorylation of forkhead box O transcription factor (FoxO)1 and FoxO3a. The protective effects of hEC-SOD were attributed to enhanced nuclear translocation of nuclear factor E2-related factor 2 (Nrf2) and subsequently increased expression of NAD(P)H dehydrogenase 1 and heme oxygenase-1. Consequently, hEC-SOD recovered from systemic and renal inflammation and apoptosis, as reflected by the decreases of serum and renal monocyte chemoattractant protein-1 and tumor necrosis factor-α levels and increases of BCL-2/BAX ratio in diabetic kidney. hEC-SOD also improved oxidative stress and resulted in increased renal and urinary 8-hydroxy-2'-deoxyguanosine and 8-isoprostane levels in db/db mice. In cultured human glomerular endothelial cells, hEC-SOD ameliorated apoptosis and oxidative stress caused by high glucose exposure through activation of AMPK and PGC-1α and dephosphorylation of FoxOs.
Innovation: These findings demonstrated for the first time that EC-SOD can potentially ameliorate hyperglycemia-induced oxidative stress, apoptosis, and inflammation through activation of AMPK and its downstream pathways in diabetic kidneys.
Conclusions: EC-SOD is a potential therapeutic target for treatment of type 2 DN through intrarenal AMPK-PGC-1α-Nrf2 and AMPK-FoxOs signaling. Antioxid. Redox Signal. 28, 1543-1561.
Rahayu I, Arfian N, Kustanti C, Wahyuningsih M Bioimpacts. 2025; 15:30129.
PMID: 39963561 PMC: 11830129. DOI: 10.34172/bi.30129.
Wang Y, Li T, Wang F, Yao X, Bai Q, Su H Int J Biol Sci. 2025; 21(2):632-657.
PMID: 39781471 PMC: 11705649. DOI: 10.7150/ijbs.104404.
Liu J, Meng L, Liu Z, Lu M, Wang R Sci Rep. 2024; 14(1):7083.
PMID: 38528189 PMC: 10963792. DOI: 10.1038/s41598-024-57794-5.
PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms.
Ye S, Zhang M, Tang S, Li B, Chen W Mol Biol Rep. 2024; 51(1):304.
PMID: 38361088 DOI: 10.1007/s11033-024-09232-y.
Nam H, Lim J, Kim T, Kim E, Oum S, Bae S Antioxidants (Basel). 2023; 12(12).
PMID: 38136160 PMC: 10740975. DOI: 10.3390/antiox12122040.